PC
PTCT icon

Passport Capital’s PTC Therapeutics PTCT Stock Holding History

Passport Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,755
Closed -$203K – 231
2014
Q1 		$203K Buy
+7,755
New +$208K 0.01% 152

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Passport Capital's PTCT Position: Q2 2014 in Review

Passport Capital sold out of PTC Therapeutics (PTCT) in Q2 2014, closing a stake of 7,755 shares — an estimated $203K sold.

Passport Capital first reported a position in PTCT in Q1 2014 and held it in 1 quarter. The position peaked at $203K in Q1 2014. 84 funds tracked by Wall St. Rank hold PTCT as of Q2 2014.

  • Passport Capital reported no remaining PTC Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Passport Capital sold 7,755 PTC Therapeutics shares in Q2 2014, an estimated $203K.
  • Passport Capital first reported a position in PTC Therapeutics in Q1 2014 and held it in 1 quarter.
  • Passport Capital's PTC Therapeutics position peaked at $203K in Q1 2014.
  • 84 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.